Boston Scientific to buy Silk Road Medical in $1.16 billion deal
Boston Scientific Corporation announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System, the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER Leadless Pacemaker (LP).
The FDA has elevated a pair of separate recalls from Route 92 Medical and Boston Scientific for issues stemming from their cardiovascular catheters for treating strokes and diagnosing conditions in the heart.
FDA classifies recall of Boston Scientific device as `most serious`
The Federal Trade Commission is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire the neuromodulation developer Axonics, a move that could push back the closing of the deal.
WSJ's is the latest media report on a potential bid for Shockwave Medical after Bloomberg News reported last year that Boston Scientific (BSX.N), opens new tab was weighing an offer for the heart device maker.
US FDA approves Boston Scientific's drug-coated heart device
Boston Scientific has received FDA approval for its Agent drug-coated balloon sized to fit within blocked or constricted coronary arteries, nearly a decade after it made its European debut.
Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery
Sept 19 (Reuters) - Medical devices maker Boston Scientific (BSX.N) said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million, gaining access to an FDA-cleared therapy for chronic pain.